Effects of sacubitril/valsartan on hypertensive heart disease: the REVERSE-LVH randomized phase 2 trial.
Saved in:
| Title: | Effects of sacubitril/valsartan on hypertensive heart disease: the REVERSE-LVH randomized phase 2 trial. |
|---|---|
| Authors: | Lee V; National Heart Research Institute of Singapore, National Heart Centre Singapore, Singapore, Singapore., Dalakoti M; Department of Cardiology, National University Heart Centre Singapore, National University Health System, Singapore, Singapore., Zheng Q; Cochrane Singapore, Singapore, Singapore., Toh DF; National Heart Research Institute of Singapore, National Heart Centre Singapore, Singapore, Singapore., Boubertakh R; National Heart Research Institute of Singapore, National Heart Centre Singapore, Singapore, Singapore., Bryant JA; Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore., Aw TC; Department of Laboratory Medicine, Changi General Hospital, Singapore, Singapore., Lee CH; Department of Cardiology, National University Heart Centre Singapore, National University Health System, Singapore, Singapore., Richards AM; Christchurch Heart Institute, University of Otago, Christchurch, New Zealand., Butler J; Baylor Scott and White Research Institute, Dallas, TX, USA.; Department of Medicine, University of Mississippi School of Medicine, Jackson, MS, USA., Díez J; Centre of Applied Medical Research (CIMA) and School of Medicine, University of Navarra, Pamplona, Spain.; Centre for Network Biomedical Research of Cardiovascular Diseases (CIBERCV), Carlos III Institute of Health, Madrid, Spain., Foo R; Department of Cardiology, National University Heart Centre Singapore, National University Health System, Singapore, Singapore.; Cardiovascular Metabolic Disease Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Cook SA; National Heart Research Institute of Singapore, National Heart Centre Singapore, Singapore, Singapore.; Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore.; Cardiovascular & Metabolic Disorders SRP, Duke-NUS Medical School, Singapore, Singapore., Lam CS; National Heart Research Institute of Singapore, National Heart Centre Singapore, Singapore, Singapore.; Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore.; Cardiovascular & Metabolic Disorders SRP, Duke-NUS Medical School, Singapore, Singapore., Le TT; National Heart Research Institute of Singapore, National Heart Centre Singapore, Singapore, Singapore.; Cardiovascular Medicine Academic Clinical Program (ACP), Duke-NUS Medical School, Singapore, Singapore., Chin CW; National Heart Research Institute of Singapore, National Heart Centre Singapore, Singapore, Singapore. cchin03m@gmail.com.; Department of Cardiology, National Heart Centre Singapore, Singapore, Singapore. cchin03m@gmail.com.; Cardiovascular Medicine Academic Clinical Program (ACP), Duke-NUS Medical School, Singapore, Singapore. cchin03m@gmail.com. |
| Source: | Nature communications [Nat Commun] 2025 Jul 30; Vol. 16 (1), pp. 6981. Date of Electronic Publication: 2025 Jul 30. |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-025-62203-0 |
